scholarly journals Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C

2016 ◽  
Vol 19 (5) ◽  
pp. 544-551 ◽  
Author(s):  
Zobair M. Younossi ◽  
Maria Stepanova ◽  
Linda Henry
Keyword(s):  
Clinical Trials ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Chronic Liver ◽  
Chronic Liver Disease Questionnaire ◽  
Disease Questionnaire

scholarly journals Hepatitis G virus co-infection in liver transplantation recipients with chronic hepatitis C and nonviral chronic liver disease

Hepatology ◽  
1997 ◽  
Vol 25 (5) ◽  
pp. 1271-1275 ◽  
Author(s):  
M W Fried ◽  
Y E Khudyakov ◽  
G A Smallwood ◽  
M Cong ◽  
B Nichols ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Chronic Liver ◽  
Hepatitis G Virus ◽  
Hepatitis G

Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C

2001 ◽  
Vol 195 (4) ◽  
pp. 473-481 ◽  
Author(s):  
Mimoun Nejjari ◽  
Anne Couvelard ◽  
Jean-Fran�ois Mosnier ◽  
Alain Moreau ◽  
G�rard Feldmann ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Chronic Liver

scholarly journals Protein C Deficiency in Chronic Hepatitis C

2016 ◽  
Vol 23 (1) ◽  
pp. 72-77 ◽  
Author(s):  
Aida Saray ◽  
Rusmir Mesihovic ◽  
Nenad Vanis ◽  
Mehmedović Amila
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Protein C ◽  
Chronic Liver ◽  
Fibrosis Stage ◽  
Coagulation System ◽  
Control Group

There is accumulating evidence that the coagulation system is involved in the process of fibrogenesis in chronic liver disease. Recent studies postulated a possible connection between plasmatic hypercoagulability and progression of fibrosis. The aim of the study was to investigate disorders of the coagulation system in patients with chronic hepatitis C having different extent of hepatic fibrosis well defined by liver histology. A total of 62 patients with chronic hepatitis C were recruited and categorized into 2 groups according to their histological fibrosis stage : mild/moderate fibrosis group (F0-F3 group, n = 30) and extensive fibrosis/cirrhosis group (F4-F6 group, n = 32). The control group consisted of 31 healthy individuals. The following hemostatic assays were evaluated: antithrombin III (AT), protein C (PC) activity, activated partial thromboplastin time, prothrombin time, plasma fibrinogen as well as conventional liver function test. The PC level exhibited a significant reduction in both patient groups when compared to the normal control group (89.25% ± 10.05% and 48.33% ± 15.86% vs 111.86 ± 10.90; P < .001 and P < .001). The PC was found to be the strongest associated factor to histological fibrosis stage ( r = –.834; P < .0001). Univariate and multivariate analysis showed that AT ( P = .003) and PC ( P = .0001) were the most important factors associated with advanced fibrosis. The PC ( P = .001) was found to be the only predictor of mild fibrosis. In conclusion, PC deficiency occurs in an early stage of liver fibrosis. The severity of deficiency is proportional to extent of fibrosis. The PC may have a key role in linking hypercoagulability with hepatic fibrogenesis in chronic liver disease.

scholarly journals Influence of depression on the quality of life in patients with chronic hepatitis C

2011 ◽  
Vol 139 (9-10) ◽  
pp. 645-650
Author(s):  
Sladjana Pavic ◽  
Neda Svirtlih ◽  
Jasmina Simonovic ◽  
Dragan Delic
Keyword(s):  
Quality Of Life ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Cognitive Dysfunction ◽  
Chronic Liver ◽  
Hamilton Depression Scale

Introduction. Chronic hepatitis C reduces the quality of life in patients causing fatigue, loss of self-confidence, reduced working capacity, development of depression, emotional problems, and cognitive dysfunction. Objective. The aim of the study was to identify the presence of depression in patients with chronic hepatitis C, predicting factors for its expression, and the impact of depression on the quality of life in these patients. Methods. During the prospective study, we used the Hamilton depression scale to investigate the presence of depression, generic 36-Item Short Form Health Survey (SF-36) and Chronic Liver Diseases Questionnaire (CLDQ) to examine the quality of life in 100 patients with chronic hepatitis C, 30 patients with chronic hepatitis B, 30 patients with chronic liver disease non- viral aetiology and 50 healthy persons. Results. A significantly higher presence of depression, and cognitive dysfunction in patients with chronic hepatitis C were noted as compared to the healthy individuals (p=0.00). In relation to non-viral patients with chronic liver disease, depression was significantly less present (p=0.004). Depression was rare in younger patients. The largest number of patients with chronic hepatitis C was without depression. The presence of depression caused deterioration of the physical and mental components of the quality of life. Multivariate analysis showed that the most significant positive predictive factor for the presence of depression was married life (B=0.278; SE=0.094; p=0.004). Conclusion. The presence of depression was more often in patients with chronic hepatitis C viral infection compared to healthy population and was correlated with decline in the quality of life. Depression is more pronounced in the elderly and intravenous drug addicts. The lowest depression is expected in patients who are not married.

Validation of the Brazilian version of Chronic Liver Disease Questionnaire

2012 ◽  
Vol 22 (1) ◽  
pp. 167-172 ◽  
Author(s):  
Samantha Mucci ◽  
Vanessa de Albuquerque Citero ◽  
Adriano Miziara Gonzalez ◽  
Luciana Geocze ◽  
Stephan Geocze ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Brazilian Version ◽  
Chronic Liver Disease Questionnaire ◽  
Disease Questionnaire

scholarly journals Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus

2004 ◽  
Vol 41 (3) ◽  
pp. 180-184 ◽  
Author(s):  
Angelo Alves de Mattos ◽  
Eliana Buksztejn Gomes ◽  
Cristiane Valle Tovo ◽  
Cláudio Osmar Pereira Alexandre ◽  
José Oscar dos Reis Remião
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Virus Infection ◽  
Hepatitis B ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Hepatitis C Virus Infection ◽  
Chronic Hepatitis C Virus

BACKGROUND: Considering the immunosuppression of patients with chronic liver disease, their response to vaccination is discussed in literature. AIMS: To evaluate the response of hepatitis B vaccine in patients with chronic hepatitis C virus infection. METHODS: This is a prospective study in which 85 patients with chronic hepatitis C virus infection (46.8 ± 9.4 years, 44.7% males) and 46 healthy adults (36.7 ± 11.1 years; 39.1% males) were evaluated. Confirmation of hepatitis C virus was obtained by the technique of polymerase chain reaction. Viral load was determined by the branched DNA method in 74 patients, and genotype was determined by sequencing in 73 patients. All patients and healthy adults received three doses of Engerix B® vaccine IM (at 0, 30 and 180 days). Serological responses to the vaccine were divided into three categories: seroprotection, when anti-HBs was >100 mUI/mL; seroconversion, when anti-HBs was 10-99 mUI/mL, and non-reagent, when anti-HBs was <10 mUI/mL. RESULTS: The response of hepatitis B vaccine as determined 1 month following dose 3 was seroprotection in 37.7%, seroconversion in 17.6% and non-reagent in 44.7% among patients and 84.8%, 13.0%, 2.2%, respectively in healthy adults. The number of non-reagent responses was significantly higher among those patients with chronic liver disease. Sixty-five patients with chronic hepatitis were compared to 20 compensated cirrhotic patients in concern to the response to vaccine, but no difference was found. The response to vaccine in patients with genotypes 2 or 3 (n = 40) was better than in those with genotype 1 (n = 33). Response was not related to serum HCV-RNA concentration. CONCLUSION: The number of non-responders was higher in patients with chronic hepatitis C virus infection, irrespective of histological status and viral load. It is suggested that such patients should receive a double dose of vaccine, particularly the ones with genotype 1.

Sign in / Sign up

Export Citation Format

Share Document